Non-small Cell Lung Cancer Treatment Market Size Share Trends Forecast 2026

Non-small Cell Lung Cancer Treatment Market Report Analyses competitive environment such as key players, future trends, growths, challenges and acquisitions in the market.
 
SEATTLE - Sept. 24, 2021 - PRLog -- Global Non-small Cell Lung Cancer Treatment Market, by Type (Adenocarcinoma, Squamous Cell Carcinoma, Large Cell Carcinoma, and Large Cell Neuroendocrine Tumors), by Treatment (Chemotherapy, Targeted Therapy (Bevacizumab (Avastin), Necitumumab (Portrazza), and Ramucirumab (Cyramza)), and Immunotherapy (Nivolumab (Opdivo), Atezolizumab (Tecentriq), and Others)), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) was estimated to be valued at US$  19,161.7 million in 2019, and is expected to exhibit a CAGR of 9.3% over the forecast period (2019-2027), as highlighted in a new report published by Coherent Market Insights.

Increasing product launches of biosimilars of Bevacizumab is expected to drive growth of the Non-small cell lung cancer treatment market over the forecast period. For instance, in July 2019, Amgen and Allergan plc collaborated and launched MVASI (bevacizumab-awwb), a biosimilar to Avastin (bevacizumab) in combination with chemotherapy for Non-small cell lung cancer.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/241

Browse 26 Market Data Tables and 33 Figures spread through 175 Pages and in-depth TOC on "Global Non-small Cell Lung Cancer Treatment Market , by Type (Adenocarcinoma, Squamous Cell Carcinoma, Large Cell Carcinoma, and Large Cell Neuroendocrine Tumors), by Treatment (Chemotherapy, Targeted Therapy (Bevacizumab (Avastin), Necitumumab (Portrazza) and Ramucirumab (Cyramza)), and Immunotherapy (Nivolumab (Opdivo), Atezolizumab (Tecentriq), and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Global Forecast to 2027"

For instance, in March 2019, Eli Lily and Company announced the positive result for its Phase 3 RELAY study of CYRAMZA (ramucirumab), meeting primary endpoint of progression-free survival (PFS) and exhibited impressive improvement in patients that lived without their cancer spreading or growing after treatment. CYRAMZA is indicated for the treatment of Non-small cell lung cancer.

Browse Research Report: https://www.coherentmarketinsights.com/market-insight/non-small-cell-lung-cancer-market-241

Key Takeaways of the Global Non-small Cell Lung Cancer Treatment Market:

The global Non-small cell lung cancer treatment market is expected to exhibit a CAGR of 9.3% over the forecast period (2019-2027), owing to increasing launches of product for non-small cell lung cancer treatment

Major players operating in the global Non-small cell lung cancer treatment market include Pfizer Inc., AstraZeneca plc, F. Hoffmann-La Roche Ltd., Eli Lilly and Company, Boehringer Ingelheim GMBH, Novartis AG, Bristol-Myers Squibb Company, and Merck & Co., Inc.

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/241

Contact
Mr. Shah
sales@coherentmarketinsights.com
+1-206-701-6702
End
Source: » Follow
Email:***@coherentmarketinsights.com
Posted By:***@coherentmarketinsights.com Email Verified
Tags:Healthcare
Industry:Health
Location:Seattle - Washington - United States
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Coherent Market Insights News
Trending
Most Viewed
Daily News



Like PRLog?
9K2K1K
Click to Share